New cocktail of drugs shows promise for tough lung cancer
NCT ID NCT05384015
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial is testing whether adding two targeted drugs (pembrolizumab and lenvatinib) to standard chemotherapy can help people with extensive-stage small cell lung cancer live longer without their cancer growing. The study involves 46 participants who have not had prior treatment for this advanced stage. Researchers are monitoring safety and how well the tumors respond.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pembrolizumab, lenvatinib, carboplatin, and etoposide
- What this could lead to
- If successful, this combination could offer a new first-line treatment option that improves how long people with extensive-stage small cell lung cancer live without their disease getting worse.
- What could go wrong
- This is a small, early-phase (phase II) trial with only 46 participants and no comparison group, so results may not be definitive. The combination also carries risks of side effects from multiple drugs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER EXTENSIVE STAGE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Complejo Hospitalario de Navarra
Pamplona, Pamplona, 31008, Spain
-
Hospital 12 De Octubre
Madrid, Madrid, 28041, Spain
-
Hospital Clínic De Barcelona
Barcelona, Barcelona, 08036, Spain
-
Hospital Clínico de Valencia
Valencia, Valencia, 46010, Spain
-
Hospital De Basurto
Bilbao, Bilbao, 48013, Spain
-
Hospital General Universitario de Alicante
Alicante, Alicante, 03010, Spain
-
Hospital General Universitario de Valencia
Valencia, Valencia, 46014, Spain
-
Hospital Parc Taulí
Barcelona, Barcelona, 08208, Spain
-
Hospital Son Espases
Palma de Mallorca, Palma de Mallorca, 07120, Spain
-
Hospital Universitari Vall d' Hebron
Barcelona, Barcelona, 08035, Spain
-
Hospital Universitario Fundación Jiménez Díaz
Madrid, Madrid, 28040, Spain
-
Hospital Universitario Lucus Augusti
Lugo, Lugo, 27003, Spain
-
Hospital Universitario Puerta de Hierro
Majadahonda, Madrid, 28222, Spain
-
Hospital Universitario Regional de Málaga
Málaga, Málaga, 29010, Spain
-
Hospital de la Santa Creu i Sant Pau
Barcelona, Barcelona, 08041, Spain
-
Hospitalario Universitario A Coruña
A Coruña, La Coruña, 15006, Spain
-
ICO Badalona, Hospital Germans Trias i Pujol
Badalona, Barcelona, 08916, Spain
-
ICO Girona, Hospital Josep Trueta
Girona, Girona, 17007, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at Hard-to-Treat lung cancer
- New writing therapy aims to ease fear in advanced cancer patients
- New drug combo aims to outperform standard care in aggressive lung cancer
- New drug combo aims to keep lung cancer in check after initial treatment
- Engineered immune cells take aim at tough lung cancer
- New triple therapy shows promise for tough lung cancer